Skip to main content

Remote Job Finders (RJF)

Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward

While Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy body dementia.

Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare

InnoCare Pharma is the latest addition to Eli Lilly’s dealmaking spree, which includes some of the biggest acquisitions this year: up to $7 billion for Kelonia Therapeutics in April and up to $7.8 billion for Centessa Pharmaceuticals in March.

Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s study

Amgen is awaiting another Phase 3 readout for the investigational Sjögren’s disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an FDA application.

Pharmas face off for manufacturing talent amidst reshoring efforts

As pharmas reshore manufacturing, they’re squaring off with each other to find the right personnel to staff up their plants. That task is challenging given the limited talent pool, difficulty filling critical roles and, in some cases, competition from data centers.
Scroll to top